0
Your cart

Your cart is empty

Browse All Departments
  • All Departments
Price
  • R5,000 - R10,000 (2)
  • -
Status
Brand

Showing 1 - 2 of 2 matches in All Departments

Epigenetics and Disease - Pharmaceutical Opportunities (Hardcover, 2011 ed.): Susan M. Gasser, En Li Epigenetics and Disease - Pharmaceutical Opportunities (Hardcover, 2011 ed.)
Susan M. Gasser, En Li
R5,464 Discovery Miles 54 640 Ships in 10 - 15 working days

Epigenetics has emerged recently as an important area of molecular biological studies. Epigenetic modifications lead to potentially heritable but reversible alterations in the expression of genes that determine cell fate. Epigenetic misregulation is thus often linked to degenerative diseases, cancer and neuronal disorders. Recent biomedical interest in this regulatory system stems from the fact that epigenetic, in contrast to genetic, alterations are in principle amenable to pharmacological intervention. A few epigenetically active drugs, for example histone deacetylase inhibitors (HDACi) and DNA methyltransferase (DNMT) inhibitors, have been approved by FDA for treatment of cancers such as CTCL, MDS, and AML. This volume explores the scientific background for clinical applications of epigenetically active drugs. Included are descriptions of epigenetic controls over gene expression, the post-transcriptional silencing of genes by RNA interference (RNAi) and microRNAs, as well as new findings from stem cell research which are relevant to pharmacological applications. Content Level Research

Epigenetics and Disease - Pharmaceutical Opportunities (Paperback, 2011 ed.): Susan M. Gasser, En Li Epigenetics and Disease - Pharmaceutical Opportunities (Paperback, 2011 ed.)
Susan M. Gasser, En Li
R5,423 Discovery Miles 54 230 Ships in 10 - 15 working days

Epigenetics has emerged recently as an important area of molecular biological studies. Epigenetic modifications lead to potentially heritable but reversible alterations in the expression of genes that determine cell fate. Epigenetic misregulation is thus often linked to degenerative diseases, cancer and neuronal disorders. Recent biomedical interest in this regulatory system stems from the fact that epigenetic, in contrast to genetic, alterations are in principle amenable to pharmacological intervention. A few epigenetically active drugs, for example histone deacetylase inhibitors (HDACi) and DNA methyltransferase (DNMT) inhibitors, have been approved by FDA for treatment of cancers such as CTCL, MDS, and AML. This volume explores the scientific background for clinical applications of epigenetically active drugs. Included are descriptions of epigenetic controls over gene expression, the post-transcriptional silencing of genes by RNA interference (RNAi) and microRNAs, as well as new findings from stem cell research which are relevant to pharmacological applications.

Free Delivery
Pinterest Twitter Facebook Google+
You may like...
Loot
Nadine Gordimer Paperback  (2)
R383 R318 Discovery Miles 3 180
Anamino Beef Protein (250g)
R289 R189 Discovery Miles 1 890
First Aid Dressing No 3
R5 Discovery Miles 50
Samurai Sword Murder - The Morne Harmse…
Nicole Engelbrecht Paperback R330 R284 Discovery Miles 2 840
Cadac Pizza Stone (33cm)
 (18)
R398 Discovery Miles 3 980
Casio LW-200-7AV Watch with 10-Year…
R999 R884 Discovery Miles 8 840
Man Alone - Mandela's Top Cop, Exposing…
Caryn Dolley Paperback R310 R225 Discovery Miles 2 250
Bostik Glu Tape
R38 Discovery Miles 380
Cable Guys Controller and Smartphone…
R399 R349 Discovery Miles 3 490
Trade Professional Drill Kit Cordless…
 (9)
R2,223 Discovery Miles 22 230

 

Partners